# DESCRIPTION

## STATEMENT OF GOVERNMENT RIGHTS

- acknowledge government rights

## FIELD OF THE INVENTION

- introduce non-invasive methods for detecting tumor-specific alterations

## BACKGROUND

- discuss limitations of current methods for detecting minimal residual disease

## SUMMARY

- introduce non-invasive methods for detecting tumor-specific alterations
- outline applications of the methods

## Definitions

- define terms used in the invention
- define "about" or "approximately"
- define "aligned", "alignment", "mapped" or "aligning", "mapping"
- define "alternative allele" or "ALT"
- define "cancer"
- define other terms used in the invention

## DETAILED DESCRIPTION

- describe matched cfDNA and WBC sequencing approach

### Genomes and Cancer

- introduce cancer genome sequencing
- motivate liquid biopsy
- describe limitations of current liquid biopsy methods
- outline method of detecting tumor specific mutations
- describe applications of detecting tumor specific mutations
- detail enzymatic steps for creating sequencing library
- introduce sequencing methods
- describe high-throughput sequencing
- detail SOLiD technology
- explain ion semiconductor sequencing
- describe Illumina sequencing
- outline single molecule real-time sequencing
- discuss sequence reads and assembly
- describe computational analysis and modeling

## EXAMPLES

### Example 1: Matched White Blood Cell and Cell-free DNA Analyses for Prediction of Therapeutic Response in Patients with Cancer

- introduce study hypothesis
- describe experimental study design
- outline patient selection and characteristics
- detail sample preparation and sequencing methods
- explain data analysis and mutation identification
- summarize statistical analysis methods
- introduce study on matched white blood cell and cell-free DNA analyses for prediction of therapeutic response in patients with cancer
- describe CRITICS study and patient selection
- outline sequencing approach and identification of tumor-specific alterations
- present results on detection of clonal hematopoiesis and tumor-specific alterations
- analyze correlation between mutant allele fractions in WBCs and cfDNA
- evaluate preoperative ctDNA as a surrogate biomarker for pathological response in gastric cancer
- discuss minimal residual disease prediction after surgery in gastric cancer
- summarize discussion on limitations of current methods for estimating disease recurrence risk
- highlight the potential of ctDNA analysis for minimal residual disease assessment in gastric cancer
- conclude on the study's findings and implications for future clinical trials

### Example 2: Early Detection and Detection of Minimal Residual Disease in Stage II and III Colorectal Cancer Patients Using a Noninvasive, White Blood Cell-Guided Liquid Biopsy Approach to Identify Mutations as Biomarkers

- introduce colorectal cancer statistics
- describe limitations of current CRC screening methods
- present white blood cell-guided liquid biopsy approach
- analyze baseline and post-resection liquid biopsies
- identify and remove hematopoietic and germline alterations
- detect tumor-derived mutations in plasma
- discuss results and implications for early detection and disease monitoring

### Example 3. Matched Leukocyte DNA Guided Liquid Biopsy Approaches for Response Monitoring in the Context of Immunotherapy for Metastatic Lung Cancer Patients

- describe study design and cohort characteristics
- classify plasma variants using matched leukocyte DNA sequencing
- evaluate predictive and prognostic performance of ctDNA molecular responses with and without filtering out CH-derived mutations

### Example 4: Matched Leukocyte DNA Guided Liquid Biopsy Approaches for Response Monitoring in the Context of Immunotherapy for Early Stage Esophageal Cancer Patients

- demonstrate utility of serial liquid biopsies
- summarize clinical utility of matched plasma-leukocyte DNA sequencing approach

## Other Embodiments

- disclaim limitations

